Inhibrx Inc (INBX)
34.14
-0.05
(-0.15%)
USD |
NASDAQ |
May 24, 16:00
34.14
0.00 (0.00%)
After-Hours: 20:00
Inhibrx Free Cash Flow (Quarterly): -64.17M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -64.17M |
| December 31, 2023 | -60.26M |
| September 30, 2023 | -55.06M |
| June 30, 2023 | -42.62M |
| March 31, 2023 | -39.97M |
| December 31, 2022 | -30.87M |
| September 30, 2022 | -30.82M |
| June 30, 2022 | -27.24M |
| March 31, 2022 | -27.06M |
| December 31, 2021 | -22.89M |
| September 30, 2021 | -13.84M |
| June 30, 2021 | -22.79M |
| Date | Value |
|---|---|
| March 31, 2021 | -21.66M |
| December 31, 2020 | -16.00M |
| September 30, 2020 | -14.18M |
| June 30, 2020 | -11.67M |
| March 31, 2020 | -7.479M |
| December 31, 2019 | -12.28M |
| September 30, 2019 | -1.484M |
| June 30, 2019 | -14.47M |
| March 31, 2019 | -5.654M |
| June 30, 2018 | -13.52M |
| March 31, 2018 | -2.189M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-64.17M
Minimum
Mar 2024
-1.484M
Maximum
Sep 2019
-26.84M
Average
-22.84M
Median
Free Cash Flow (Quarterly) Benchmarks
| Gilead Sciences Inc | 2.114B |
| Pfizer Inc | 386.00M |
| Arcus Biosciences Inc | -6.00M |
| Axonics Inc | -12.30M |
| Moderna Inc | -1.185B |